American journal of veterinary research · 1998
Temporal effects of an infusion of dobutamine hydrochloride in horses anesthetized with halothane.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Young L E, Blissitt K J, Clutton R E, Molony V
Аннотация
OBJECTIVE: To evaluate temporal hemodynamic effects of dobutamine in horses anesthetized with halothane.
ANIMALS: 8 adult Thoroughbreds.
PROCEDURE: Anesthesia was induced by i.v. administration of romifidine and ketamine and maintained using halothane in oxygen. After 60 minutes, dobutamine was administered i.v. for 60 minutes at 4 micrograms/kg of body weight/min. Measurements of left ventricular function were obtained by transesophageal echocardiography and cardiac catheterization.
RESULTS: Mean, systolic, diastolic, aortic, pulmonary arterial, and left and right ventricular end-diastolic and systolic pressures, maximal rate of increase of intraventricular pressure (LVdp/dtmax), maximum acceleration (dv/dtmax) and velocity (Vmax) of aortic blood flow, cardiac output, and left ventricular velocity time integral were significantly increased, whereas left ventricular pre-ejection period and ejection time significantly decreased. Cardiac output, LVdp/dtmax, Vmax, and dv/dtmax increased throughout infusion. Heart rate was significantly less after 10 minutes and significantly greater at 60 minutes than before infusion. Supraventricular tachycardia developed in 2 horses. Cardiac output, LVdp/dtmax, Vmax, dv/dtmax, left ventricular and aortic systolic pressures, and mean aortic pressure had not returned to control values 30 minutes after infusion was discontinued.
CONCLUSIONS: At this dosage, dobutamine did not achieve peak effect on many hemodynamic variables within 40 minutes of commencing infusion, and effects of 60-minute infusion persisted after infusion was discontinued.
CLINICAL RELEVANCE: Dobutamine has a hemodynamic profile suited to treatment of low cardiac output in anesthetized horses; however, sustained administration may be associated with supraventricular tachycardia and a protracted time to peak effect.
ANIMALS: 8 adult Thoroughbreds.
PROCEDURE: Anesthesia was induced by i.v. administration of romifidine and ketamine and maintained using halothane in oxygen. After 60 minutes, dobutamine was administered i.v. for 60 minutes at 4 micrograms/kg of body weight/min. Measurements of left ventricular function were obtained by transesophageal echocardiography and cardiac catheterization.
RESULTS: Mean, systolic, diastolic, aortic, pulmonary arterial, and left and right ventricular end-diastolic and systolic pressures, maximal rate of increase of intraventricular pressure (LVdp/dtmax), maximum acceleration (dv/dtmax) and velocity (Vmax) of aortic blood flow, cardiac output, and left ventricular velocity time integral were significantly increased, whereas left ventricular pre-ejection period and ejection time significantly decreased. Cardiac output, LVdp/dtmax, Vmax, and dv/dtmax increased throughout infusion. Heart rate was significantly less after 10 minutes and significantly greater at 60 minutes than before infusion. Supraventricular tachycardia developed in 2 horses. Cardiac output, LVdp/dtmax, Vmax, dv/dtmax, left ventricular and aortic systolic pressures, and mean aortic pressure had not returned to control values 30 minutes after infusion was discontinued.
CONCLUSIONS: At this dosage, dobutamine did not achieve peak effect on many hemodynamic variables within 40 minutes of commencing infusion, and effects of 60-minute infusion persisted after infusion was discontinued.
CLINICAL RELEVANCE: Dobutamine has a hemodynamic profile suited to treatment of low cardiac output in anesthetized horses; however, sustained administration may be associated with supraventricular tachycardia and a protracted time to peak effect.